Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Grunenthal
Deal Size : Not Applicable
Deal Type : Not Applicable
Grünenthal Completes Recruitment for QUTENZA® Post-Surgical Neuropathic Pain Trial
Details : Qutenza (capsaicin) topical patch is approved for neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy, being investigated for post-surgical neuropathic pain.
Brand Name : CA-008
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 07, 2024
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Grunenthal
Deal Size : Not Applicable
Deal Type : Not Applicable
First Patient Enrolled in a Phase III study with QUTENZA® in Post-Surgical Neuropathic Pain
Details : The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.
Brand Name : Qutenza
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2021
LOOKING FOR A SUPPLIER?
Reset All
